Hyperhidrosis

Qbrexza Now Available for the Treatment of Primary Axillary Hyperhidrosis

By October 01, 2018

A single cloth should be used to apply Qbrexza to both underarms.

Novel Treatment for Primary Axillary Hyperhidrosis Gets FDA Approval

By June 29, 2018

The approval was supported by Phase 3 data from the ATMOS-1 and ATMOS-2 trials which evaluated the absolute change from baseline in sweat production after treatment with Qbrexza, and the proportion of patients who achieved ≥4-point improvement from baseline in their sweating severity (as measured by the Axillary Sweating Daily Diary [ASDD]).

Investigational Hyperhidrosis Therapy Found to Be Safe, Effective

By October 13, 2017

Daily treatment with glycopyrronium tosylate in the Phase 3, open-label ARIDO trial was generally well-tolerated during 44 weeks of treatment.